Written on: September 23, 2025 by SprayTM
Aptar Pharma announced that its Unidose Liquid System (UDS)—a single-use nasal delivery system designed for systemic drug absorption via the nasal mucosa—is the delivery system for the Enbumyst bumetanide nasal spray from Corstasis Therapeutics, recently approved by the U.S. Food & Drug Administration (FDA). This approval marks the first intranasal loop diuretic for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults.
Enbumyst offers patients a convenient, self-administered alternative to traditional oral and intravenous forms in an outpatient-focused therapy. Clinical data indicated a faster onset of sodium excretion and a 33% increase in absorption speed compared to oral administration, according to a study from the American Heart Association.
“We are pleased to see our Unidose System continually supporting innovative therapies that expand access and convenience for patients,” said Alex Theodorakis, President, Aptar Pharma Prescription.
“This approval reflects the growing potential of nasal delivery platforms in systemic treatment and reinforces Aptar’s commitment to enabling patient-centric solutions.”
Added Ben Esque, CEO of Corstasis Theraeutics, “Innovating to address patient needs is central to Corstasis’ mission and Enbumyst provides an option we believe has the potential to allow patients to maintain independence in the treatment of their edema.”
